Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The study is supported by Tyra Biosciences, Inc., a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. This study will investigate a patient’s tumor DNA through their blood and urine samples to provide information on their treatment and what options might be available if their disease worsens.
Search
Recent Posts
See AllBy: Steven Loeb Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there are more startups than ever, there's
Matterworks, Inc., developers of the world's most powerful metabolomics platform, which accelerates the discovery, development, and manufacturing of biologics and gene therapies, today announces updat
Luna, the leading provider of in-home physical therapy, has teamed up with UCI Health, to expand access to patient care by providing in-home physical therapy across Orange County, California. With a f
